secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inogen Inc (INGN)
CIK:        0001294133
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-066968
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inogen reports FY2025 revenue $348.7M (+3.9%); net loss narrows to $22.7M; first positive adj. EBITDA in four years
--------------------------------------------------------------------------------

- Revenue $348.7M (+3.9% YoY); net loss $22.7M improved from $35.9M loss in 2024.
- Adjusted EBITDA turned positive at $2.7M (vs -$9.5M in 2024); Q4 adj. EBITDA -$1.7M improved from -$3.6M.
- Cash and equivalents $120.9M with zero debt; Board authorized $30M share repurchase program through Dec 2027.
- International POC sales grew 18.4% in 2025; introduced new products Voxi 5, Aurora CPAP masks, Simeox airway clearance.
- Total gross margin 44.2% in 2025 vs 46.1% in 2024 due to channel mix.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1294133/000119312526066968/0001193125-26-066968-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1294133/000119312526066968/ingn-20260220.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-066968

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer